Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Letter from the Editor Next Article
Outcomes in patients on alemtuzumab with thyroid adverse events »
« Letter from the Editor Next Article
Outcomes in patients on alemtuzumab with thyroid adverse events »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

August 27, 2019
Prognostic blood and MRI biomarkers
December 9, 2021
Ibudilast reduced retinal atrophy in primary progressive MS
November 25, 2020
Therapeutic potential of anti-MOSPD2 monoclonal antibodies
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy